Merck Signs a Clinical Trial Collaboration with Xilio for Anti-CTLA-4 Monoclonal Antibody Program

 Merck Signs a Clinical Trial Collaboration with Xilio for Anti-CTLA-4 Monoclonal Antibody Program

Shots:

  • The companies collaborated to evaluate XTX101 + Keytruda for patients with solid tumors. The planned P-I study will be conducted by Xilio and is designed to evaluate the safety & efficacy of XTX101 as a monothx. and in combination with Keytruda for solid tumors
  • Xilio plans to submit an IND for XTX101 to the US FDA in Q2’21. Following the IND clearance, Xilio expects to initiate a P-I study. In preclinical studies, XTX101 was well-tolerated and achieved robust tumor growth inhibition
  • XTX101 is a tumor-selective anti-CTLA-4 mAb designed to pinpoint the anti-CTLA-4 effect geographically within the tumor without off-tumor peripheral effects

Click here to­ read full press release/ article | Ref: Businesswire | Image: Businesswire

Tuba Khan

Tuba Khan is Senior Editor at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in the Life sciences industry. She covers Biopharma, MedTech, and Digital health segments. Tuba also has an experience of digital and social media marketing and runs the campaigns independently. She can be contacted on tuba@pharmashots.com

Related post